• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS EX filed by GeoVax Labs Inc.

    4/17/26 9:04:42 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email
    POS EX 1 govx20260417d_posex.htm FORM POS EX govx20260417d_posex.htm
     

    As filed with the Securities and Exchange Commission on April 15, 2026

     

    Registration No. 333-281973



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 3

    FORM S-1

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    GEOVAX LABS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    2834

    87-0455038

    (State or other jurisdiction of

    incorporation or organization)

    (Primary Standard Industrial

    Classification Code Number)

    (I.R.S. Employer

    Identification Number)

     

     

    1955 Lake Park Drive, Suite 300, Smyrna, Georgia 30080

    Tel: (678) 384-7220

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    David A. Dodd

    President & Chief Executive Officer

    GeoVax Labs, Inc.

    1955 Lake Park Drive, Suite 300

    Smyrna, Georgia 30080

    Tel: (678) 384-7220

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    F. Reid Avett, Esq.

    Womble Bond Dickinson (US) LLP

    2001 K Street, NW, Suite 400 South
    Washington, D.C. 20006

    Tel: (202) 857-4425

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Amendment No. 2.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

     

     

     

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

           

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

           
       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this Post-Effective Amendment No. 2 to registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Post-Effective Amendment No. 2 to registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     



     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 (Commission File No. 333-281973) of GeoVax Labs, Inc. is being filed to add Exhibit 23.1 (Consent of Independent Registered Public Accounting Firm), which was inadvertently not included in the Post-Effective Amendment No. 2 which was filed on April 15, 2026.

     

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 13. Other Expenses of Issuance and Distribution.

     

    The following table sets forth the fees and expenses payable in connection with the registration of the securities hereunder. All amounts are estimates except the SEC registration fee.

    Item

     

    Amount to be paid

     

    SEC registration fee

      $ 593  

    Legal fees and expenses

        10,000  

    Accounting fees and expenses

        3,500  

    Miscellaneous fees and expenses

        2,000  

    Total

      $ 16,093  

     

     

    Item 14. Indemnification of Directors and Officers.

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Our bylaws provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. Our bylaws also provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.

     

    II-1

     

     

    Under our bylaws, expenses (including attorneys’ fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as we deem appropriate.

     

    The indemnification and advancement of expenses provided by our bylaws is not exclusive, both as to action in such person’s official capacity and as to action in another capacity while holding such office.

     

    Our bylaws also provide that we may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Company would have the power to indemnify such person against such liability under our bylaws. The Company maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.

     

    In October 2006, GeoVax and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs. McNally, Reynolds, Kollintzas and Spencer. Pursuant to these agreements, we have agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, we will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are our directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Company, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 15. Recent Sales of Unregistered Securities.

     

    On August 10, 2023, we issued 11,883 shares of our restricted common stock to Outside the Box Capital, Inc. pursuant to a professional services agreement. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.

     

    On September 28, 2023, we issued 4,892 shares of our restricted common stock to Acorn Management Partners, LLC pursuant to a professional relations and consulting agreement. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.

     

    On January 2, 2024, we issued 6,703 shares of our restricted common stock to Acorn Management Partners, LLC pursuant to a professional relations and consulting agreement. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.

     

    On September 30, 2025, the Company entered into a securities purchase agreement with purchasers party thereto in a private placement offering of up to 11,904,768 shares of our common stock issuable upon the exercise of those certain common warrants. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.

     

    On February 12, 2026, the Company entered into a securities purchase agreement with purchasers party thereto in a private placement offering of up to 865,804 shares of our common stock issuable upon the exercise of those certain common warrants. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.

     

    II-2

     

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibit Index

    Exhibit

     

    Number

    Description

    3.1

    Restated Certificate of Incorporation filed April 12, 2024 (17)

    3.2

    Certificate of Amendment to Certificate of Incorporation filed January 9, 2026 (30)

    3.3

    Bylaws (as amended May 23, 2024) (19)

    4.1

    Form of Stock Certificate representing the Company’s Common Stock, par value $0.001 per share (30)

    4.2

    Form of Common Stock Purchase Warrant, dated September 28, 2021 (10)

    4.3

    Form of Common Stock Purchase Warrant, dated May 21, 2024 (18)

    4.4

    Form of Common Stock Purchase Warrant, dated July 12, 2024 (20)

    4.5

    Form of Common Stock Purchase Warrant, dated August 21, 2024 (21)

    4.6

    Form of Common Stock Purchase Warrant, dated August 30, 2024 (22)

    4.7

    Form of Common Stock Purchase Warrant, dated March 25, 2025 (24)

    4.8

    Warrant Amendment Agreement, dated March 23, 2025 (24)

    4.9

    Form of Common Stock Purchase Warrant, dated July 2, 2025 (25)

    4.10

    Form of Common Stock Purchase Warrant, dated September 30, 2025 (26)

    4.11

    Form of Common Stock Purchase Warrant, dated December 22, 2025 (29)

    4.12

    Form of Pre-Funded Warrant, dated February 17, 2026 (31)

    4.13

    Form of Series A-1 Common Warrant, dated February 17, 2026 (31)

    4.14

    Form of Series A-2 Common Warrant, dated February 17, 2026 (31)

    4.15

    Form of Warrant Amendment Agreement, dated February 17, 2026 (31)

    4.16

    Form of Inducement Letter, dated March 31, 2026 (34)

    4.17

    Form of Common Stock Purchase Warrant, dated March 31, 2026 (34)

    5.1

    Opinion of Womble Bond Dickinson (US) LLP (33)

    10.1**

    Employment Agreement between GeoVax Labs, Inc. and David A. Dodd (4)

    10.2**

    Employment Agreement between GeoVax, Inc. and Mark W. Reynolds (2)

    10.2.1**

    Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and Mark W. Reynolds (3)

    10.3**

    Employment Agreement between GeoVax, Inc. and Mark J. Newman, PhD (12)

    10.3.1**

    Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and Mark J. Newman, PhD (13)

    10.4**

    Employment Agreement between GeoVax, Inc. and Kelly T. McKee, MD (15)

    10.4.1**

    Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and Kelly T. McKee, MD (15)

    10.5**

    Employment Agreement between GeoVax, Inc. and John W. Sharkey, PhD (13)

    10.5.1**

    Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and John W. Sharkey, PhD (13)

    10.6**

    GeoVax Labs, Inc. 2020 Stock Incentive Plan (7)

    10.6.1**

    GeoVax Labs, Inc. 2023 Stock Incentive Plan (14)

    10.6.2**

    GeoVax Labs, Inc. 2025 Stock Incentive Plan (27)

    10.6.3**

    Form of Stock Option Agreement under the GeoVax Labs, Inc. 2020 Stock Incentive Plan (6)

    10.6.4**

    Form of Stock Option Agreement under the GeoVax Labs, Inc. 2023 Stock Incentive Plan (32)

    10.6.5**

    Form of Stock Option Agreement under the GeoVax Labs, Inc. 2025 Stock Incentive Plan (32)

    10.7

    Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases, dated October 22, 2020 (8) ***

    10.8

    Patent and Biological Materials License Agreement for Internal Research Use with the National Institute of Allergy and Infectious Diseases, dated November 25, 2020 (9) ***

    10.9

    Membership Agreement (Portal Innovation Science Square Labs), dated August 1, 2025 (28)

    10.10

    Office Lease, dated September 15, 2025 (28)

    10.11

    Summary of the GeoVax Labs, Inc. Director Compensation Plan (12)

    10.12

    Assignment and License Agreement by and between GeoVax, Inc. and PNP Therapeutics, Inc. dated September 28, 2021 (11) ***

    10.13

    License Agreement by and between GeoVax, Inc. and City of Hope, dated November 9, 2021 (11) ***

    10.13.1

    Amendment to License Agreement, dated April 11, 2023, between GeoVax, Inc. and City of Hope (16) ***

    10.14

    Securities Purchase Agreement, dated May 16, 2024 (18)

    10.15

    Securities Purchase Agreement, dated July 11, 2024 (20)

    10.16

    Securities Purchase Agreement, dated August 20, 2024 (21)

    10.17

    Securities Purchase Agreement, dated August 28, 2024 (22)

    10.18

    Securities Purchase Agreement, dated March 23, 2025 (24)

    10.19

    Sales Agreement, by and between the Company and A.G.P./Alliance Global Partners (23)

    10.20

    Placement Agency Agreement between the Company and A.G.P./Alliance Global Partners (24)

     

    II-3

     

     

    10.21

    Placement Agency Agreement between the Company and Roth Capital Partners, LLC (25)

    10.22

    Placement Agency Agreement between the Company and Roth Capital Partners, LLC (26)

    10.23

    Securities Purchase Agreement, dated July 2, 2025 (25)

    10.24

    Securities Purchase Agreement, dated September 30, 2025 (26)

    10.25

    Placement Agency Agreement between the Company and Roth Capital Partners, LLC (29)

    10.26

    Securities Purchase Agreement, dated December 22, 2025 (29)

    10.27

    Securities Purchase Agreement, dated February 12, 2026 (31)

    21.1

    Subsidiaries of the Registrant (5)

    23.1*

    Consent of Wipfli LLP (U.S. PCAOB Auditor Firm ID 344)

    23.2

    Consent of Womble Bond Dickinson (US) LLP (included in Exhibit 5.1)

    24.1

    Power of Attorney (included on Signature page of registrant’s Registration Statement on Form S-1 (File No. 333-281973) filed September 6, 2024)

    101.INS

    Inline XBRL Instance Document (1)

    101.SCH

    Inline XBRL Taxonomy Extension Schema Document (1)

    101.CAL

    Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)

    101.DEF

    Inline XBRL Taxonomy Extension Definition Linkbase Document (1)

    101.LAB

    Inline XBRL Taxonomy Extension Label Linkbase Document (1)

    101.PRE

    Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)

    104

    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     


    *

    Filed herewith.

    **

    Indicates a management contract or compensatory plan or arrangement.

    ***

    Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as the Company has determined (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the Company if publicly disclosed.

     

    (1)

    These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections.

    (2)

    Incorporated by reference from the registrant’s Annual Report on Form 10-K filed March 8, 2010.

    (3)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed October 23, 2013.

    (4)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed September 7, 2018.

    (5)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed November 7, 2019.

    (6)

    Incorporated by reference from the registrant’s Annual Report on Form 10-K filed March 23, 2021.

    (7)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed November 12, 2021.

    (8)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed October 26, 2020.

    (9)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed November 30, 2020.

    (11)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed September 29, 2021.

    (11)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed November 10, 2021.

    (12)

    Incorporated by reference from the registrant’s Annual Report on Form 10-K filed March 9, 2022.

    (13)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed August 3, 2022.

    (14)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed December 8, 2022.

    (15)

    Incorporated by reference from the registrant’s Annual Report on Form 10-K filed March 23, 2023.

    (16)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed May 4, 2023.

    (17)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed May 14, 2024.

    (18)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed May 21, 2024.

    (19)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed May 23, 2024.

    (20)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed July 12, 2024.

    (21)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed August 21, 2024.

    (22)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed August 30, 2024.

    (23)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed September 25, 2024.

    (24)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed March 25, 2025.

    (25)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed July 2, 2025.

    (26)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed September 30, 2025.

    (27)

    Incorporated by reference from the registrant’s Registration Statement on Form S-8 filed June 6, 2025.

    (28)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed November 13, 2025.

    (29)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed December 22, 2025.

    (30)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed January 12, 2026.

    (31)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed February 17, 2026.

    (32)

    Incorporated by reference from the registrant’s Annual Report on Form 10-K filed April 15, 2026.

     

    II-4

     

     

    (33)

    Incorporated by reference from registrant’s Registration Statement on Form S-1 (File No. 333-281973) filed September 6, 2024.

    (34)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed March 31, 2026.

     

     

    Item 17. Undertakings

     

    (a)

    The undersigned Registrant hereby undertakes:

     

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

     

     

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

     

     

    (2)

    That for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

    (4)

    That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

     

    (i)

    Each prospectus filed by the registrant pursuant to Rule 424(b)(3) (§ 230.424(b)(3) of this chapter) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

    (ii)

    Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

     

    II-5

     

     

     

    (5)

    That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

    (i)

    Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

     

    (ii)

    Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

     

    (iii)

    The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

     

    (iv)

    Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

     

    (b)

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

    II-6

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Smyrna, State of Georgia, on April 15, 2026.

     

     

    GEOVAX LABS, INC.

       
     

    By:

    /s/ David A. Dodd

     

    Name:

    David A. Dodd

     

    Title:

    Chief Executive Officer

     

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Name

     

    Position

     

    Date

    /s/ David A. Dodd

     

    Director

    President and Chief Executive Officer

     

    April 15, 2026

    David A. Dodd

     

    (Principal Executive Officer)

       
             

    /s/ Mark W. Reynolds

     

    Chief Financial Officer

     

    April 15, 2026

    Mark W. Reynolds

     

    (Principal Financial and Accounting Officer)

       
             

    *

     

    Director

     

    April 15, 2026

    Randal D. Chase

           
             

    *

     

    Director

     

    April 15, 2026

    Dean G. Kollintzas

           
             

    *

     

    Director

     

    April 15, 2026

    Nicole Lemerond

           
             

    *

     

    Director

     

    April 15, 2026

    Robert T. McNally

           
             

    *

     

    Director

     

    April 15, 2026

    Jayne Morgan

           
             

    *.

     

    Director

     

    April 15, 2026

    John N. Spencer, Jr.

           
             

    By: /s/ Mark W. Reynolds

           

    Mark W. Reynolds

    Attorney-in-Fact

           

     

    II-7
    Get the next $GOVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    2/19/2026Buy → Hold
    D. Boral Capital
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by GeoVax Labs Inc.

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    10/20/25 9:11:05 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    6/6/25 9:51:40 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

    D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

    4/15/25 7:54:48 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

    Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

    4/15/25 7:54:17 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

    MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – TodaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go b

    9/24/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

    MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered,

    9/23/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    $GOVX
    SEC Filings

    View All

    SEC Form POS EX filed by GeoVax Labs Inc.

    POS EX - GeoVax Labs, Inc. (0000832489) (Filer)

    4/17/26 9:05:12 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS EX filed by GeoVax Labs Inc.

    POS EX - GeoVax Labs, Inc. (0000832489) (Filer)

    4/17/26 9:04:15 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS EX filed by GeoVax Labs Inc.

    POS EX - GeoVax Labs, Inc. (0000832489) (Filer)

    4/17/26 9:04:42 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    4/11/25 1:23:33 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    4/10/25 4:01:15 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Leadership Updates

    Live Leadership Updates

    View All

    GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

    Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

    8/8/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

    Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

    1/8/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

    First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

    12/20/22 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Financials

    Live finance-specific insights

    View All

    GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

    Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

    11/12/24 4:00:00 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

    GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

    11/5/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

    Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

    8/6/24 4:00:00 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GeoVax Labs Inc.

    SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

    2/14/24 3:38:25 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    2/10/21 3:16:30 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care